



Blissco Receives Positive EU GMP Inspection Report

Not for distribution in the U.S. or to U.S. Newswires

Vancouver, British Columbia – March 7, 2019 – [Blissco Cannabis Corp. \(CSE: BLIS\)](#) ([OTCQB: HSTRF](#)) ([FRA: GQ4B](#)), (“Blissco”) or the (“Company”) is a Canadian wellness cannabis brand based in British Columbia, a licensed processor and producer of premium dried cannabis and cannabis oil, and a licensed distributor of dried cannabis products. The Company is pleased to share it has received a positive initial European Union Good Manufacturing Practices (“EU GMP”) report from the German Health Authority that recently completed its four-day inspection of the Blissco facility.

“Receiving our initial GMP Inspection Report from the German Health Authority is a key milestone in earning our GMP certification,” said Damian Kettlewell, Blissco CEO. “Our GMP certification will allow us to obtain the necessary permits and complete our first export to the rapidly growing medical cannabis sector in Germany via our distribution partner Pharmadrug Production GmbH. GMP certification will also open up more market and product opportunities for Blissco, providing us with additional opportunities to enhance shareholder value.”

Last week, Blissco presented at the Canadian Childhood Cannabinoid Clinical Trials Workshop at Sick Kids Hospital. “The researchers and pediatricians that we met with indicated that they could only partner with GMP certified facilities for these kinds of clinical trials. Their feedback added further validation that our ongoing investment in earning this certification will help support Blissco in establishing new strategic partnerships and ultimately drive growth,” said Damian Kettlewell, Blissco CEO.

About Blissco Cannabis Corp.

Blissco Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a Canadian wellness cannabis brand based in British Columbia and a multi-licensed processor, cultivator, and distributor of premium cannabis.

Blissco owns and operates an 18,000 square foot, state-of-the-art GPP facility located in Metro Vancouver, British Columbia with extraction, cultivation and processing rooms. Blissco is supplying premium cannabis and small-batch Reserve whole flower and dried flower pre-rolls to the Canadian and global marketplace with a growing list of provincial cannabis boards and international distribution partners.

With a license to process cannabis oil acquired in August 2018, Blissco's extraction lab is also in operation preparing a line of full spectrum oils for distribution in 2019.

Learn more at blissco.com.

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

1 604 484-9119

investors@blissco.com

Cautionary Statements

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.